BR112018010650A8 - pró-fármacos de um inibidor de jak composto para o tratamento da doença inflamatória gastrointestinal - Google Patents

pró-fármacos de um inibidor de jak composto para o tratamento da doença inflamatória gastrointestinal

Info

Publication number
BR112018010650A8
BR112018010650A8 BR112018010650A BR112018010650A BR112018010650A8 BR 112018010650 A8 BR112018010650 A8 BR 112018010650A8 BR 112018010650 A BR112018010650 A BR 112018010650A BR 112018010650 A BR112018010650 A BR 112018010650A BR 112018010650 A8 BR112018010650 A8 BR 112018010650A8
Authority
BR
Brazil
Prior art keywords
jak inhibitor
prodrugs
compound
treatment
inflammatory disease
Prior art date
Application number
BR112018010650A
Other languages
English (en)
Other versions
BR112018010650A2 (pt
Inventor
D Long Daniel
A A Wilton Donna
Loo Mandy
J Brassil Patrick
Hudson Ryan
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of BR112018010650A2 publication Critical patent/BR112018010650A2/pt
Publication of BR112018010650A8 publication Critical patent/BR112018010650A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/16—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms containing two or more hetero rings
    • C12P17/165—Heterorings having nitrogen atoms as the only ring heteroatoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

a invenção proporciona compostos que são pró-fármacos de um agente inibidor de jak para a distribuição direcionada do inibidor de jak ao trato gastrointestinal de um mamífero. a invenção também proporciona composições farmacêuticas compreendendo os compostos, métodos de utilização dos compostos para tratar doenças inflamatórias gastrointestinais e processos e intermediários úteis para preparar os compostos.
BR112018010650A 2015-11-24 2016-11-22 pró-fármacos de um inibidor de jak composto para o tratamento da doença inflamatória gastrointestinal BR112018010650A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562259273P 2015-11-24 2015-11-24
US62/259,273 2015-11-24
PCT/US2016/063254 WO2017091544A1 (en) 2015-11-24 2016-11-22 Prodrugs of a jak inhibitor compound for treatment of gastrointestinal inflammatory disease

Publications (2)

Publication Number Publication Date
BR112018010650A2 BR112018010650A2 (pt) 2018-11-13
BR112018010650A8 true BR112018010650A8 (pt) 2019-02-26

Family

ID=57518004

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018010650A BR112018010650A8 (pt) 2015-11-24 2016-11-22 pró-fármacos de um inibidor de jak composto para o tratamento da doença inflamatória gastrointestinal

Country Status (32)

Country Link
US (3) US10435428B2 (pt)
EP (1) EP3380486B1 (pt)
JP (2) JP6778747B2 (pt)
KR (1) KR20180080330A (pt)
CN (1) CN108290918B (pt)
AU (1) AU2016359494B2 (pt)
BR (1) BR112018010650A8 (pt)
CA (1) CA3003283A1 (pt)
CL (1) CL2018001345A1 (pt)
CO (1) CO2018005327A2 (pt)
CY (1) CY1122918T1 (pt)
DK (1) DK3380486T3 (pt)
EA (1) EA035816B1 (pt)
ES (1) ES2784523T3 (pt)
HR (1) HRP20200561T1 (pt)
HU (1) HUE049775T2 (pt)
IL (1) IL259076B (pt)
LT (1) LT3380486T (pt)
ME (1) ME03757B (pt)
MX (1) MX2018006282A (pt)
MY (1) MY189979A (pt)
NZ (1) NZ742574A (pt)
PH (1) PH12018501037A1 (pt)
PL (1) PL3380486T3 (pt)
PT (1) PT3380486T (pt)
RS (1) RS60237B1 (pt)
SG (1) SG11201803686UA (pt)
SI (1) SI3380486T1 (pt)
TW (1) TWI703147B (pt)
UA (1) UA121270C2 (pt)
WO (1) WO2017091544A1 (pt)
ZA (1) ZA201802967B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3865481A1 (en) 2015-11-03 2021-08-18 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
EP3371185B1 (en) 2015-11-03 2020-09-30 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
HUE049775T2 (hu) 2015-11-24 2020-10-28 Theravance Biopharma R&D Ip Llc Gasztrointesztinális gyulladásos betegség kezelésére szolgáló JAK inhibitor vegyület elõgyógyszerei
FR3060567B1 (fr) * 2016-12-19 2019-05-24 Ecole Normale Superieure De Lyon Substrat de glycosidase fluorogene et procede de detection associe
WO2018165250A1 (en) * 2017-03-08 2018-09-13 Theravance Biopharma R&D Ip, Llc Glucuronide prodrugs of tofacitinib
NZ759764A (en) 2017-05-23 2022-07-01 Theravance Biopharma R&D Ip Llc Glucuronide prodrugs of janus kinase inhibitors
CN110662755A (zh) * 2017-05-23 2020-01-07 施万生物制药研发Ip有限责任公司 托法替尼的硫代氨基甲酸酯前药
CA3062067A1 (en) * 2017-06-05 2018-12-13 Flagship Pioneering Innovations V, Inc. Multibiotic agents and methods of using the same
US10933069B2 (en) 2018-01-05 2021-03-02 Cybrexa 1, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
KR20190110459A (ko) * 2018-03-20 2019-09-30 삼진제약주식회사 신규 염, 이의 제조 방법 및 이를 포함하는 약학 조성물
US20220257600A1 (en) 2018-06-20 2022-08-18 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor
CN111094314B (zh) * 2018-08-15 2022-08-12 江苏豪森药业集团有限公司 含有葡糖苷酸衍生物jak抑制剂的前药及其制备方法和应用
KR20210074291A (ko) * 2018-09-06 2021-06-21 아레나 파마슈티칼스, 인크. 자가면역 및 염증성 장애의 치료에 유용한 화합물
CN109134564B (zh) * 2018-09-21 2022-03-11 合肥锐思生物医药有限公司 乳果糖糖苷衍生物、其制备方法及其用途
WO2020102519A1 (en) * 2018-11-15 2020-05-22 Janssen Biotech, Inc. Methods and compositions for prediction of response to a therapy of an inflammatory bowel disease
CN113692278A (zh) * 2018-12-19 2021-11-23 因赛特公司 用于治疗胃肠道疾病的jak1途径抑制剂
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
TW202116778A (zh) 2019-07-10 2021-05-01 美商斯布雷克薩二號公司 作為治療劑之細胞毒素之肽結合物
EP3996749A1 (en) 2019-07-10 2022-05-18 Cybrexa 3, Inc. Peptide conjugates of microtubule-targeting agents as therapeutics
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021097074A1 (en) * 2019-11-13 2021-05-20 New York University Intestinal organoid co-culture systems and methods for treating or preventing a disease or disorder associated with immune response-mediated tissue injury
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021231272A1 (en) * 2020-05-14 2021-11-18 Theravance Biopharma R&D Ip, Llc Administration of gut-selective jak3 inhibitor
CN113943312A (zh) * 2020-07-17 2022-01-18 轶诺(浙江)药业有限公司 一类肠道裂解型共药及其制备和用途
EP4232146A4 (en) * 2020-10-22 2024-07-31 Biora Therapeutics Inc METHODS OF TREATMENT AND PREDICTION OF NON-RESPONSE TO ANTI-TNF TREATMENT IN SUBJECTS WITH DISEASES OF THE GASTROINTESTINAL TRACT
EP4351584A1 (en) * 2021-06-07 2024-04-17 The Regents of the University of California Compositions and methods for treating celiac disease
WO2023225463A2 (en) * 2022-05-14 2023-11-23 3-D Matrix, Ltd. Novel formulations for oral administration of therapeutic agents to the gastrointestinal tract
CN115073543B (zh) * 2022-07-20 2022-11-15 北京普祺医药科技股份有限公司 一种jak抑制剂的化合物前药及其制备与应用
CN117567460A (zh) * 2022-08-08 2024-02-20 明慧医药（杭州）有限公司 一种前药化合物及其制备方法和用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993022334A1 (en) 1992-05-04 1993-11-11 Sri International Pharmaceutical compositions and methods for colonic delivery of corticosteroids
US5811388A (en) 1995-06-07 1998-09-22 Cibus Pharmaceutical, Inc. Delivery of drugs to the lower GI tract
KR100477818B1 (ko) 1999-12-10 2005-03-22 화이자 프로덕츠 인코포레이티드 피롤로[2,3-ｄ] 피리미딘 화합물
JP5946768B2 (ja) 2009-10-09 2016-07-06 インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ ３−（４−（７Ｈ−ピロロ［２，３−ｄ］ピリミジン−４−イル）−１Ｈ−ピラゾール−１−イル）−３−シクロペンチルプロパンニトリルのヒドロキシル、ケト及びグルクロニド誘導体
EP2515913A2 (en) 2009-12-23 2012-10-31 Glycomyr Inc. Use of vitamin d glycosides and sulfates for treatment of disease
CN102724967A (zh) 2009-12-31 2012-10-10 安龙制药公司 包括可释放的脲连接体的含芳香胺化合物的聚合缀合物
AU2011213198B2 (en) * 2010-02-05 2014-04-24 Zoetis Llc Pyrrolo [ 2,3-d] pyrimidine urea compounds as JAK inhibitors
US20130109720A1 (en) 2011-11-01 2013-05-02 Hoffmann-La Roche Inc. Indole inhibitors of crac
US20140357557A1 (en) * 2013-05-31 2014-12-04 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
JP6697403B2 (ja) * 2014-06-24 2020-05-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 炎症性腸疾患の処置のための方法及び医薬組成物
HUE049775T2 (hu) 2015-11-24 2020-10-28 Theravance Biopharma R&D Ip Llc Gasztrointesztinális gyulladásos betegség kezelésére szolgáló JAK inhibitor vegyület elõgyógyszerei
AU2016379454B2 (en) 2015-12-23 2021-01-28 The University Of British Columbia Lipid-linked prodrugs
CN106496233B (zh) 2016-09-26 2018-05-15 东南大学 吡咯并嘧啶类化合物、其制备方法及其用途

Also Published As

Publication number Publication date
IL259076B (en) 2021-05-31
SI3380486T1 (sl) 2020-07-31
CY1122918T1 (el) 2021-10-29
DK3380486T3 (da) 2020-05-18
IL259076A (en) 2018-06-28
LT3380486T (lt) 2020-05-11
WO2017091544A1 (en) 2017-06-01
PL3380486T3 (pl) 2020-07-27
EP3380486B1 (en) 2020-02-19
PH12018501037A1 (en) 2019-01-28
ES2784523T3 (es) 2020-09-28
US20210179655A1 (en) 2021-06-17
US10435428B2 (en) 2019-10-08
ZA201802967B (en) 2019-04-24
ME03757B (me) 2021-04-20
CA3003283A1 (en) 2017-06-01
JP2020196742A (ja) 2020-12-10
HUE049775T2 (hu) 2020-10-28
US20170145044A1 (en) 2017-05-25
CN108290918A (zh) 2018-07-17
US10961267B2 (en) 2021-03-30
AU2016359494A1 (en) 2018-06-14
RS60237B1 (sr) 2020-06-30
EP3380486A1 (en) 2018-10-03
SG11201803686UA (en) 2018-06-28
KR20180080330A (ko) 2018-07-11
MY189979A (en) 2022-03-22
BR112018010650A2 (pt) 2018-11-13
PT3380486T (pt) 2020-05-22
MX2018006282A (es) 2019-01-21
TW201720827A (zh) 2017-06-16
CO2018005327A2 (es) 2018-05-31
EA035816B1 (ru) 2020-08-14
HRP20200561T1 (hr) 2020-06-26
CL2018001345A1 (es) 2018-06-22
TWI703147B (zh) 2020-09-01
NZ742574A (en) 2018-11-30
US11608354B2 (en) 2023-03-21
US20190389895A1 (en) 2019-12-26
EA201891248A1 (ru) 2018-10-31
UA121270C2 (uk) 2020-04-27
JP6778747B2 (ja) 2020-11-04
AU2016359494B2 (en) 2021-01-07
JP2019501133A (ja) 2019-01-17
CN108290918B (zh) 2021-06-08

Similar Documents

Publication Publication Date Title
BR112018010650A2 (pt) pró-fármacos de um inibidor de jak composto para o tratamento da doença inflamatória gastrointestinal
PH12019550050A1 (en) Isoxazole analogs as fxr agonists and methods of use thereof
EA201791874A1 (ru) Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
EA201792231A1 (ru) Ингибиторы индоламин-2,3-диоксигеназы и способы их применения
BR112018072545A2 (pt) inibidores da arginase e suas aplicações terapêuticas
TW201613901A (en) New compounds
MX2018004043A (es) Prevencion, tratamiento y reversion de enfermedad usando cantidades terapeuticamente efectivas de acidos grasos activados.
BR112018006866A2 (pt) compostos agonistas de ppar, composições farmacêuticas e métodos de uso dos mesmos
BR112014009415A2 (pt) inibidores de arginase e suas aplicações terapêuticas
CL2014001838A1 (es) Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras.
BR112018005905A2 (pt) ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto?
BR112019021867A2 (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenil
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
BR112019025230A2 (pt) Anéis 5-5 fundidos como inibidores de c5a
TR201900148T4 (tr) Kansere karşı yeni maddeler olarak sübstitüe edilmiş 2,4 diamino-kinolin.
MX2017005861A (es) Metodos para el control transcripcional objetivo en regiones del super mejorador.
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
AU2016380190A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
BR112015023878A2 (pt) composto, composição farmacêutica, e, uso de um composto
EA202191548A1 (ru) Ингибиторы плазменного калликреина человека
PH12016501548B1 (en) Cholesteryl ester transfer protein (cetp) inhibitor and pharmaceutical compositions comprising said inhibitor for use in the treatment or prevention of cardiovascular diseases
BR112017006264A2 (pt) derivados de nucleosídeo substituído com 4?-vinila como inibidores de replicação de rna do vírus sincitial respiratório

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2749 DE 12-09-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.